AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12592542 — intervention group
Group type: EXPERIMENTAL
Intervention: General Function Score
Number of subjects: 289
Study 12592542 — intervention group
Group type: EXPERIMENTAL
Intervention: Zung Depression Scale
Number of subjects: 289
Study 12592542 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scale (VAS) of back pain
Number of subjects: 289
Study 12592542 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment outcomes
Number of subjects: 289
Study 10926124 — intervention group
Group type: EXPERIMENTAL
Intervention: audio‐CASI interview at both intake and retest
Number of subjects: 0
Study 10926124 — intervention group
Group type: COMPARATOR
Intervention: face‐to‐face interview at both intake and retest
Number of subjects: 0
Study 10926124 — intervention group
Group type: EXPERIMENTAL
Intervention: audio‐CASI interview at intake and face‐to‐face interview at retest
Number of subjects: 0
Study 10926124 — intervention group
Group type: EXPERIMENTAL
Intervention: face‐to‐face interview at intake and audio‐CASI interview at retest
Number of subjects: 0
Study 9110682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice cocktail
Number of subjects: 0
Study 9110682 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8240450 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate 800 mg daily
Number of subjects: 297
Study 8240450 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg daily
Number of subjects: 297
Study 3513767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazmegrel 50-200 mg p.o.
Number of subjects: 0
Study 3513767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazmegrel 100 mg b.i.d.
Number of subjects: 0
Study 3513767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazmegrel 200 mg t.i.d.
Number of subjects: 0
Study 3513767 — intervention group
Group type: EXPERIMENTAL
Intervention: Dazmegrel (all doses studied)
Number of subjects: 0
Study 3513767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31882151 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (40 mg of dimethylprednisolone, injected once)
Number of subjects: 32
Study 31882151 — intervention group
Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (PRP) injection (3 separate injections, 1 week apart)
Number of subjects: 32
Study 28939343 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led home-based exercise and cognitive behavioral therapy (E&CBT)
Number of subjects: 72
Study 28939343 — intervention group
Group type: COMPARATOR
Intervention: Services as usual (Control)
Number of subjects: 72
Study 26626991 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE910 (0.001, 0.01, 0.1, 0.3, or 1 mg/kg for Japanese; 0.1, 0.3, or 1 mg/kg for white)
Number of subjects: 64
Study 26626991 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE910
Number of subjects: 64
Study 26626991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 24408120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate
Number of subjects: 90
Study 21953509 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 week community exercise program
Number of subjects: 39
Study 21953509 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 39
Study 19438941 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration (GBR) with bovine hydroxyapatite (BHA)
Number of subjects: 20
Study 17270510 — intervention group
Group type: EXPERIMENTAL
Intervention: Early sensorimotor robotic training, 4 hours a week for 5 weeks
Number of subjects: 35
Study 17270510 — intervention group
Group type: COMPARATOR
Intervention: Robotic device exposure, 30 minutes a week, twice a week (exercises with unimpaired upper limb)
Number of subjects: 35
Study 16091494 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training (n = 14)
Number of subjects: 50
Study 16091494 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (n = 12)
Number of subjects: 50
Study 16091494 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HI; n = 14)
Number of subjects: 50
Study 16091494 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 50
Study 16091494 — intervention group
Group type: EXPERIMENTAL
Intervention: Detraining after resistance training
Number of subjects: 50
Study 16091494 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (including control)
Number of subjects: 50
Study 12182293 — intervention group
Group type: EXPERIMENTAL
Intervention: Chin autogenous bone grafts
Number of subjects: 10
Study 12182293 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest autogenous bone grafts
Number of subjects: 10
Study 10090300 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetable juice consumption
Number of subjects: 0
Study 10090300 — intervention group
Group type: COMPARATOR
Intervention: Raw or cooked vegetables consumption
Number of subjects: 0
Study 7844684 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron, 20 microgram/kg intravenously, plus up to two more doses within 24 hours if required
Number of subjects: 88
Study 7844684 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine, 0.3 to 0.5 mg/kg intravenously every 4 to 6 hours, plus dexamethasone, 2 mg/m2 intravenously every 8 hours
Number of subjects: 88
Study 2201223 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 38
Study 2201223 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline plus perphenazine
Number of subjects: 38
Study 106800 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutrition
Number of subjects: 0
Study 106800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral elementary diet
Number of subjects: 0
Study 106800 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without any gastro-intestinal tract disease)
Number of subjects: 0
Study 30946703 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizole and paracetamol
Number of subjects: 200
Study 30946703 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen and paracetamol
Number of subjects: 200
Study 27846055 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP5‐HB‐IPV‐Hib
Number of subjects: 1250
Study 27846055 — intervention group
Group type: COMPARATOR
Intervention: Control (Infanrix‐hexa)
Number of subjects: 1250
Study 27846055 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1250
Study 25756274 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg once daily for 2 weeks (group 2)
Number of subjects: 99
Study 25756274 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended ureteral catheter drainage for 48 hours (group 3)
Number of subjects: 99
Study 25756274 — intervention group
Group type: COMPARATOR
Intervention: Indwelling double J stent for 2 weeks (group 1)
Number of subjects: 99
Study 23945445 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale (Y-BOCS) treatment response
Number of subjects: 288
Study 23945445 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale (Y-BOCS) symptom remission
Number of subjects: 288
Study 23945445 — intervention group
Group type: EXPERIMENTAL
Intervention: Yale-Brown Obsessive Compulsive Scale (Y-BOCS) wellness
Number of subjects: 288
Study 21790236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline 400 mg for 7 months
Number of subjects: 75
Study 21790236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 19366323 — intervention group
Group type: EXPERIMENTAL
Intervention: HPG containing ocular lubricant (Systane Lubricant Eye Drops; Alcon) administered four times daily (QID) for 28 days
Number of subjects: 20
Study 17537785 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 microg/kg/min)
Number of subjects: 12
Study 17537785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15549468 — intervention group
Group type: EXPERIMENTAL
Intervention: Disposable PCA device (Coopdech Syrinjector)
Number of subjects: 40
Study 15549468 — intervention group
Group type: COMPARATOR
Intervention: Electronic PCA device (IVAC PCAM PCA Syringe Pump)
Number of subjects: 40
Study 11829199 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 14
Study 9605675 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 24
Study 9605675 — intervention group
Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 24
Study 9605675 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus dose of propofol
Number of subjects: 24
Study 9605675 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion of propofol at rates of 25, 50, 100, or 200 microg x kg(‐1) x min(‐1)
Number of subjects: 24
Study 9605675 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, weight, height, and lean body mass as covariates
Number of subjects: 24
Study 7531327 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum alpha‐fetoprotein (AFP) levels prior to CVS
Number of subjects: 21
Study 7531327 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum alpha‐fetoprotein (AFP) levels 1 week after CVS
Number of subjects: 21
Study 7531327 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in AFP levels following CVS
Number of subjects: 21
Study 7531327 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in beta hCG levels following CVS
Number of subjects: 21
Study 7531327 — intervention group
Group type: EXPERIMENTAL
Intervention: Difference in AFP or beta hCG levels prior to and 1 week following CVS
Number of subjects: 21
Study 3132571 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin depot (sustak forte)
Number of subjects: 123
Study 3132571 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 123
Study 3132571 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 123
Study 3132571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sustak-propranolol combinations
Number of subjects: 123
Study 29546523 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy (SFBT)
Number of subjects: 44
Study 29546523 — intervention group
Group type: COMPARATOR
Intervention: Active Control (AC)
Number of subjects: 44
Study 26901221 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat Aleurone
Number of subjects: 14
Study 26901221 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat Bran
Number of subjects: 14
Study 26901221 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 25697830 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocapnic trial (end‐tidal carbon dioxide clamped at baseline levels)
Number of subjects: 0
Study 25697830 — intervention group
Group type: EXPERIMENTAL
Intervention: Poikilocapnic trial (end‐tidal carbon dioxide uncontrolled)
Number of subjects: 0
Study 25697830 — intervention group
Group type: EXPERIMENTAL
Intervention: Both trials (hypotension with and without hypocapnia)
Number of subjects: 0
Study 23807155 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg TAF
Number of subjects: 38
Study 23807155 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg TAF
Number of subjects: 38
Study 23807155 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg TAF
Number of subjects: 38
Study 23807155 — intervention group
Group type: COMPARATOR
Intervention: 300 mg TDF
Number of subjects: 38
Study 20647087 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive sonic irrigation system (EndoActivator)
Number of subjects: 0
Study 20647087 — intervention group
Group type: COMPARATOR
Intervention: Standard syringe irrigation (control group)
Number of subjects: 0
Study 20647087 — intervention group
Group type: EXPERIMENTAL
Intervention: Second session of treatment with intervisit calcium hydroxide disinfection
Number of subjects: 0
Study 19072529 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher internalized homonegativity (IH)
Number of subjects: 675
Study 19072529 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic, sexual and mental health variables
Number of subjects: 675
Study 16463838 — intervention group
Group type: COMPARATOR
Intervention: Cerebral electrical impedance (CEI) measured by noninvasive Brain‐Edema Monitor in healthy volunteers
Number of subjects: 185
Study 16463838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral electrical impedance (CEI) in patients with ICH
Number of subjects: 185
Study 16463838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral electrical impedance (CEI) in patients with arterothrombotic cerebral infarction
Number of subjects: 185
Study 12204730 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug therapy (digitalis and atenolol)
Number of subjects: 160
Study 12204730 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitalis
Number of subjects: 160
Study 12204730 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 160
Study 12204730 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 160
Study 10381856 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pacing
Number of subjects: 80
Study 10381856 — intervention group
Group type: COMPARATOR
Intervention: Inactive pacing
Number of subjects: 80
Study 8921778 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hirudin (0.1 to 0.3 mg.kg‐1.h‐1)
Number of subjects: 163
Study 8921778 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hirudin (0.05 mg.kg‐1.h‐1)
Number of subjects: 163
Study 8921778 — intervention group
Group type: COMPARATOR
Intervention: heparin (target aPTT 65 to 90 seconds or 90 to 110 seconds)
Number of subjects: 163
Study 8921778 — intervention group
Group type: EXPERIMENTAL
Intervention: r-hirudin (0.3 mg.kg‐1.h‐1)
Number of subjects: 163
Study 1859005 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil 1.0 mg
Number of subjects: 12
Study 1859005 — intervention group
Group type: COMPARATOR
Intervention: Placebo (flumazenil vehicle)
Number of subjects: 12
Study 1859005 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 12
Study 6345308 — intervention group
Group type: EXPERIMENTAL
Intervention: Galphimia glauca D4 therapy
Number of subjects: 86
Study 6345308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 30610099 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal or no PAE throughout gestation
Number of subjects: 471
Study 30610099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐to‐moderate PAE with discontinuation early in gestation
Number of subjects: 471
Study 30610099 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐to‐moderate PAE sustained across gestation
Number of subjects: 471
Study 30610099 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate‐to‐high PAE with reduction early in gestation
Number of subjects: 471
Study 30610099 — intervention group
Group type: EXPERIMENTAL
Intervention: High PAE sustained across gestation
Number of subjects: 471
Study 30099066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm F (NaF) with casein phosphopeptide-amorphous calcium phosphate (CPP-ACP)
Number of subjects: 0
Study 30099066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1150 ppm F (SnF2) with amorphous calcium phosphate (ACP)
Number of subjects: 0
Study 30099066 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm F (NaF) with functionalized tri-calcium phosphate (TCP)
Number of subjects: 0
Study 30099066 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 ppm F (NaF)
Number of subjects: 0
Study 30099066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm F (MFP) with calcium sodium phosphosilicate (CSP)
Number of subjects: 0
Study 30099066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm F (MFP) with CaCO3/Arg
Number of subjects: 0
Study 30099066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1450 ppm F (NaF)
Number of subjects: 0
Study 26882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 235
Study 26882293 — intervention group
Group type: COMPARATOR
Intervention: Present‐Centered Therapy
Number of subjects: 235
Study 26882293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure or Present‐Centered Therapy
Number of subjects: 235
Study 24510401 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized cognitive counseling (PCC)
Number of subjects: 326
Study 24510401 — intervention group
Group type: COMPARATOR
Intervention: Control (HIV testing alone)
Number of subjects: 326
Study 22245233 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of levels
Number of subjects: 0
Study 22245233 — intervention group
Group type: COMPARATOR
Intervention: Method of limits
Number of subjects: 0
Study 20689853 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT abstracts
Number of subjects: 332
Study 20689853 — intervention group
Group type: EXPERIMENTAL
Intervention: Details of interventions
Number of subjects: 332
Study 20689853 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of participants randomized
Number of subjects: 332
Study 20689853 — intervention group
Group type: EXPERIMENTAL
Intervention: Study objectives
Number of subjects: 332
Study 20689853 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial registration details
Number of subjects: 332
Study 20689853 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of allocation concealment
Number of subjects: 332
Study 20689853 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding details
Number of subjects: 332
Study 20689853 — intervention group
Group type: COMPARATOR
Intervention: Chinese vs English abstracts
Number of subjects: 332
Study 17934053 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program for general practitioners based on clinical guidelines for dementia care
Number of subjects: 25
Study 17934053 — intervention group
Group type: EXPERIMENTAL
Intervention: Support from general practitioners to carers
Number of subjects: 25
Study 17113890 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 U of BTX‐A
Number of subjects: 75
Study 17113890 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 U of BTX‐A
Number of subjects: 75
Study 17113890 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 U of BTX‐A
Number of subjects: 75
Study 14703416 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 50
Study 14703416 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3 mg
Number of subjects: 50
Study 10737133 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (nicardipine hydrochloride retard tablet)
Number of subjects: 0
Study 10737133 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (trichlormethiazide)
Number of subjects: 0
Study 9001776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid lenses with low upper lid position and small palpebral aperture
Number of subjects: 8
Study 9001776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid lenses with high upper lid position and wide palpebral aperture
Number of subjects: 8
Study 9001776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid lenses interacting with the upper lid
Number of subjects: 8
Study 9001776 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid lenses with lens center of gravity behind the corneal apex
Number of subjects: 8
Study 9001776 — intervention group
Group type: EXPERIMENTAL
Intervention: High riding lenses
Number of subjects: 8
Study 1390474 — intervention group
Group type: EXPERIMENTAL
Intervention: Threads-up group (IUCD with threads contained in the uterine cavity)
Number of subjects: 445
Study 1390474 — intervention group
Group type: COMPARATOR
Intervention: Threads-down group (IUCD with threads passing through the cervix to the vagina)
Number of subjects: 445
Study 1390474 — intervention group
Group type: EXPERIMENTAL
Intervention: Threads-up group
Number of subjects: 445
Study 1390474 — intervention group
Group type: COMPARATOR
Intervention: Threads-down group
Number of subjects: 445
Study 3886608 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-Course Radiation Therapy Protocol for Carcinoma of the Base of the Tongue (RTOG #71‐02)
Number of subjects: 141
Study 31013507 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted dying agreement among surrogates
Number of subjects: 232
Study 31013507 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted dying agreement among physicians
Number of subjects: 232
Study 31013507 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous deep sedation (CDS) agreement among physicians
Number of subjects: 232
Study 31013507 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous deep sedation (CDS) agreement among surrogates
Number of subjects: 232
Study 31013507 — intervention group
Group type: COMPARATOR
Intervention: Comparison of agreement with assisted dying
Number of subjects: 232
Study 31013507 — intervention group
Group type: COMPARATOR
Intervention: Comparison of agreement with CDS
Number of subjects: 232
Study 29469593 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnosine (800 mg/d in two divided doses) plus methylphenidate (0.5-1.5 mg/kg/d)
Number of subjects: 56
Study 29469593 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methylphenidate (0.5-1.5 mg/kg/d)
Number of subjects: 56
Study 27832693 — intervention group
Group type: EXPERIMENTAL
Intervention: Distance learning (DVD with a 50-minute lecture and case simulation scenario)
Number of subjects: 120
Study 27832693 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning (50-minute lecture and case simulation scenario in a workshop)
Number of subjects: 120
Study 25301695 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored game providing personalized feedback on drinking behavior.
Number of subjects: 0
Study 25301695 — intervention group
Group type: COMPARATOR
Intervention: Control condition (waiting list) that only fills in baseline, four and eight month follow-up measurements.
Number of subjects: 0
Study 25301695 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based, computer-tailored game.
Number of subjects: 0
Study 22532165 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min) combined with cognitive training on a stop signal task (SST)
Number of subjects: 22
Study 22532165 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training on a stop signal task (SST) without active stimulation
Number of subjects: 22